Allspring Global Investments Holdings LLC Has $156.09 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Allspring Global Investments Holdings LLC increased its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 25.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,229,558 shares of the medical research company's stock after purchasing an additional 246,246 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.99% of Natera worth $156,092,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. bought a new position in Natera in the 2nd quarter worth approximately $28,000. Quarry LP increased its position in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock worth $34,000 after buying an additional 190 shares during the period. GAMMA Investing LLC increased its position in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock worth $35,000 after buying an additional 108 shares during the period. Tobam bought a new position in Natera in the 2nd quarter worth approximately $74,000. Finally, DekaBank Deutsche Girozentrale bought a new position in Natera in the 1st quarter worth approximately $83,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Price Performance

Natera stock traded up $0.05 on Friday, reaching $122.40. The company's stock had a trading volume of 985,355 shares, compared to its average volume of 1,085,650. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The company has a market cap of $15.03 billion, a price-to-earnings ratio of -39.23 and a beta of 1.53. The business's fifty day moving average price is $123.30 and its 200 day moving average price is $110.61. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $133.54.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the previous year, the firm earned ($0.97) earnings per share. The business's revenue was up 58.1% on a year-over-year basis. Equities analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on NTRA shares. The Goldman Sachs Group lifted their price target on Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday. TD Cowen boosted their price objective on Natera from $137.00 to $145.00 and gave the company a "buy" rating in a research report on Friday, August 9th. Piper Sandler restated an "overweight" rating and set a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. UBS Group lowered their price objective on Natera from $160.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. Finally, Leerink Partners boosted their price objective on Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $124.44.

Insiders Place Their Bets

In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the completion of the sale, the insider now directly owns 206,400 shares in the company, valued at $21,211,728. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $113.82, for a total transaction of $307,314.00. Following the completion of the transaction, the insider now directly owns 299,441 shares in the company, valued at approximately $34,082,374.62. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Daniel Rabinowitz sold 1,057 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the transaction, the insider now owns 206,400 shares of the company's stock, valued at approximately $21,211,728. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,765 shares of company stock worth $6,016,700 over the last ninety days. 7.60% of the stock is currently owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.